3.2. Primary Endpoint
throat
Regarding the comprehensive assessment of oral and throat discomforts, the VAS scores for total oral discomfort were significantly higher at the 1–2 h period for both the placebo and bLF treatments when compared with the baseline. However, a significant reduction in VAS scores was observed at 2 h for the bLF treatment, contrasting with the placebo treatment. Similarly, the VAS scores for total throat discomfort were significantly elevated at the 1–2 h period in the placebo and at the 2 h juncture in the bLF treatment compared to baseline levels. Again, VAS scores were significantly lower at 2 h for the bLF treatment when compared to the placebo treatment (